AMGEN Inc.

NASDAQ:AMGN   3:59:59 PM EDT
250.96
-1.42 (-0.56%)
4:07:27 PM EDT: $250.74 -0.22 (-0.09%)
Products, Earnings Announcements

FDA Approves Amgen's Riabni

Published: 12/17/2020 21:25 GMT
AMGEN Inc. (AMGN) - FDA Approves Amgen's Riabni™ (rituximab-arrx), a Biosimilar to Rituxan® (rituximab).
Amgen Inc - Riabni Will Be Made Available in U.S. in January 2021.
Amgen Inc - Wholesale Acquisition Cost (wac Or "list Price") of Riabni in U.S. Will Be 23.7% Lower Than Reference Product, Rituxan.
Amgen Inc - at Launch, Riabni Will Be Priced 16.7% Below Current Rituxan Average Selling Price (asp).
Amgen Inc - Riabni Will Be Available From Both Wholesalers and Specialty Distributors.
Revenue is expected to be $6.41 Billion
Adjusted EPS is expected to be $4.04

Next Quarter Revenue Guidance is expected to be $6.67 Billion
Next Quarter EPS Guidance is expected to be $4.28

More details on our Analysts Page.